|Bid||301.00 x N/A|
|Ask||284.80 x N/A|
|Day's Range||284.50 - 297.00|
|52 Week Range||2.01 - 388.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jun. 03, 2012|
|1y Target Est||N/A|
TEL AVIV, Israel, July 8, 2020 /CNW/ -- The Israeli subsidiary of Panaxia Global, Panaxia Labs Israel Ltd. (Panaxia Israel) (TASE:PNAX.TA - News), the largest manufacturer of medical cannabis products in Israel, issued today a preliminary revenue outlook for the second quarter of 2020. The company estimates its consolidated (non-reviewed) revenues in the second quarter of 2020 will be at least 14 million. The projected revenues for the second quarter reflect the continued growth of the company's operations with a 350%-increase of revenues in the second quarter of 2019, which totaled 3.1 million.
Blazing the Trail to European Exports: Panaxia Israel Announces Receipt of EU-GMP Certification, Required for the Manufacture and European Export of Medical Cannabis and Advanced Products
Concurrently with increasing the number of patients in Israel, we are on track to initiate export and commercial sales in Europe later this year. The consecutive, 10-quarter revenue growth is attributed to the expansion of the production, marketing, and home deliveries operations, as well as to the transition of working under the new Israeli cannabis regulation, which provides the Panaxia Israel with higher revenues per product unit.